Log In
Print this Print this

SynCon malaria DNA vaccine

  Manage Alerts
Collapse Summary General Information
Company Inovio Pharmaceuticals Inc.
DescriptionSynCon DNA vaccine targeting the pre-erythrocytic stage of the malaria parasite Plasmodium falciparum delivered with electroporation
Molecular Target P. falciparum circumsporozoite (CS) protein B9 (B9) (CSP) ; Acid phosphatase 5 tartrate resistant (ACP5) (TRAP)
Mechanism of ActionVaccine
Therapeutic ModalityPreventive vaccine: DNA vaccine
Latest Stage of DevelopmentPreclinical
Standard IndicationMalaria
Indication DetailsPrevent malaria infection
Regulatory Designation


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today